The Institute for Clinical and Economic Review (ICER) evaluated tralokinumab, abrocitinib, baricitinib, upadacitinib, and ruxolitinib cream for
atopic dermatitis. This report presents the summary of our systematic literature review and cost-effectiveness analysis and highlights the key
policy recommendations discussed at the New England Comparative Effectiveness Public Advisory Council’s public meeting on July 23, 2021. The detailed report is available at https://icer.org/wp-content/uploads/2021/08/Atopic-Dermatitis_Final-Evidence-Report_081721.pdf
